" So why the downgrade today to sell from ned davis research ? "
Why would any reasonably competent investor let that derail or otherwise interfere with their L-T investment in CELG ?!?
THAT would indeed be baffling !
Your LOGIC is impeccable (heavy sarcasm here). Exactly which clinical trials failed, what new drug competitors hit the market, etc.? Folks have the right to be either short or long, but at least do us the favor of some FACTS supporting your position.
I'd imagine not much logic, just FEAR of Kyle Bass combined with the Gilead price pressures made this analyst have a panic attack. There are a LOT of BAD biotech analysts out there, guys who should only be allowed to evaluate companies like P&G on how much toothpaste they sell. Truthfully TWITTER has a bunch of amateur and pro bio guys that are really, really good. Just check out your favorite bio plays on there $CELG etc. for some of the best info.
Novartis is developing CTL019 with the University of Pennsylvania for treating pediatric acute lymphoblastic leukemia, or ALL. In two pilot clinical studies conducted by the Children's Hospital of Philadelphia, all signs of cancer disappeared in 27 of 30 patients, while 19 of those 27 patients had remained in remission at the time the results were published. Fifteen of those 19 received no further therapy, while four patients withdrew to receive a different therapy. The results were eyebrow-raising, and CTL019 earned the U.S. Food and drug Administration's coveted Breakthrough Therapy designation
Suntrust - Celgene upcoming catalysts
Product Timing Indication Event
Hematology & Oncology
Revlimid Feb 22, 2015 Newly-diagnosed multiple myeloma PDUFA date for label expansion
Revlimid Q1 2015 Newly-diagnosed multiple myeloma EMA decision on label expansion
Abraxane H1 2015 Non-small cell lung cancer EMA approval decision
Revlimid H1 2015 Myeloma (maintenance after transplant) Phase III data from IFM2005-02 trial (OS follow-up)
Revlimid H1 2015 Myeloma (maintenance after transplant) Phase III data from CALBG 100104 trial (OS follow-up)
Pomalyst H1 2015 Relapsed multiple myeloma Japan approval decision
Revlimid ASCO (May 29-June 2) Newly-diagnosed multiple myeloma MM-020 Phase III survival follow up
Revlimid ASCO (May 29-June 2) Follicular lymphoma Meta-analysis correlation between sustained CR and PFS
Revlimid H2 2015 Chronic lymphocytic leukemia Complete enrolment of the Phase III CONTINUUM trial
Revlimid H2 2015 Newly-diagnosed multiple myeloma Japan approval decision
Vidaza H2 2015 Elderly acute myeloblastic leukemia CHMP decision
CC-122 H2 2016 Diffuse Large B Cell Lymphoma Advance Phase I/II trials
AG-221 H2 2015 IDH2-mutated acute myeloblastic leukemia Launch pivotal program
Sotatercept/luspatercept H2 2015 Beta-thalassemia Start a Phase III trial
Revlimid 2015 All indications, intellectual property Possible settlement with Natco
MOR-202 2015 Phase I data in relapsed/refractory MM Data presentation (potentially at ASCO 2015)
Revlimid + CC-292 2015 Phase I/II data in CLL Data presentation (potentially at ASCO 2015)
Revlimid Late 2016/early 2017 Follicular lymphoma Phase III study readouts
Revlimid Late 2016/early 2017 Diffuse Large B Cell Lymphoma Phase III study readouts
GED-0301 Early 2015 Crohn's disease Publication of Phase II trial data
GED-0301 Early 2015 Crohn's disease Begin an endoscopy trial
GED-0301 DDW (May 16-19) Crohn's disease Ad-hoc analysis of GED-0301 Phase II data
GED-0301 Mid-2015 Crohn's disease Launch two Phase III trials
Sotatercept 2015 End-stage renal disorder anemia Complete enrollment of a Phase IIb study
CC-220 2015 Systemic Lupus Erythemathosus Complete enrollment of a Phase IIa study
GED-0301 Early 2017+ Crohn's disease Phase III trial topline data begins to read out
If CELG doesn't yo-yo, I make no money........
I think it bottomed as well, bought more.
Man: Well, what've you got?
Waitress: Well, there's egg and bacon; egg sausage and bacon; egg and spam; egg bacon and spam; egg bacon sausage and spam; spam bacon sausage and spam; spam egg spam spam bacon and spam; spam sausage spam spam bacon spam tomato and spam;
Vikings: Spam spam spam spam...
Waitress: ...spam spam spam egg and spam; spam spam spam spam spam spam baked beans spam spam spam...
Vikings: Spam! Lovely spam! Lovely spam!
Waitress: ...or Lobster Thermidor a Crevette with a mornay sauce served in a Provencale manner with shallots and aubergines garnished with truffle pate, brandy and with a fried egg on top and spam.
Wife: Have you got anything without spam?
Waitress: Well, there's spam egg sausage and spam, that's not got much spam in it.
Wife: I don't want ANY spam!
Man: Why can't she have egg bacon spam and sausage?
Wife: THAT'S got spam in it!
Man: Hasn't got as much spam in it as spam egg sausage and spam, has it?
time again. Even after remarkable guidance and recent Q4 report. If you think about it, there aren't too many other Co's you can bet the farm on to at least double in 4-5years...and that's based on guidance CELG's said excluding everything new in trials, and their guidance seems to be on the low side consistently.
yes and no. i think technical traders are very much a part of it and a push above yesterday's close at the end of the day sets well for Tuesday's open. i like the LT story however i like to get in at a good price. i bought the dip today
More likely an ETF effect. ETF's are an ever bigger part of the market and they are especially prevalent in biotech, which as a group has been on a tear for the last two years, but event risk in any one stock can be a huge gut punch. The Kyle Bass news likely resulted in a lot of ETF selling, maybe even shorting (short term if smart). I feel confident that CELG will survive this storm just like it has the last couple of biotech selloffs last April and October. Kyle Bass will collect his short poundage from some of the weaker players and then exit the trades imo.